AbbVie Ireland

Leadership as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for AbbVie (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.

Clinical trials 226 in our ClinicalTrials.gov registers · 7 in the EU register

Showing 10 of 226, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 98 compounds

EU trials register (CTIS) 7 authorised or ongoing

• A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)2025-523819-11-00 · Phase III · Ongoing
• A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).2024-520125-36-00 · Phase I · Ongoing
• A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma2025-525105-20-00 · Phase I/II · Ongoing
• A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)2026-526282-25-00 · Phase I · Authorised
• Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-2882025-522563-15-00 · Phase III · Authorised
• A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy2025-523724-47-00 · Phase III · Ongoing
• A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis2025-523127-21-00 · Phase I · Ongoing

Recent approvals

• BoeyEMA · trenibotulinumtoxinE · 15 Jul 2026

Medicine shortages 9 in the FDA list

• Lopinavir and Ritonavir TabletUS (FDA) · resolved · updated 24 Jul 2026
• Ritonavir TabletUS (FDA) · resolved · updated 24 Jul 2026
• Ritonavir Oral PowderUS (FDA) · resolved · updated 24 Jul 2026
• Lopinavir and Ritonavir Oral SolutionUS (FDA) · resolved · updated 24 Jul 2026
• Nitroglycerin OintmentUS (FDA) · resolved · updated 14 Apr 2026
• Progesterone Vaginal GelUS (FDA) · resolved · updated 27 Mar 2026
• Pilocarpine Hydrochloride Ophthalmic SolutionUS (FDA) · resolved · updated 24 Mar 2026
• Podofilox Topical GelUS (FDA) · resolved · updated 28 Jan 2026

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 56 of its medicines · 50 current

• Atogepant for treating migraineNICE TA1172 · Optimised · 30 Jun 2026
• Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancerNICE TA1169 · Recommended · 24 Jun 2026
• Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatmentNICE TA1139 · Optimised · 11 Mar 2026
• Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaNICE TA1119 · Recommended · 7 Jan 2026
• Risankizumab for treating moderately to severely active ulcerative colitisNICE TA998 · Optimised · 22 Aug 2024
• Atogepant for preventing migraineNICE TA973 · Optimised · 15 May 2024
• Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsNICE TA954 · Optimised · 6 Mar 2024
• Upadacitinib for previously treated moderately to severely active Crohn’s diseaseNICE TA905 · Optimised · 21 Jun 2023

Appraisals of medicines whose first EU or US authorisation was held by this company, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (AbbVie): founded 2012, headquarters North Chicago, website abbvie.com. Wikidata Q14662364 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here AbbVie; Pharmacyclics Switzerland GmbH; Allergan; AbbVie Deutschland GmbH & Co. KG; AbbVie Limited; AbbVie Inc. and 4 more. Spot a wrong match? Tell us.

Group figures for AbbVie Inc., the parent company. From the annual reports AbbVie Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 8 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to AbbVie Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.